realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
102actual
Sites
26
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-20 | actual | When the study began enrolling |
| Primary completion | 2026-01-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-23 | actual | The whole study's end, after follow-up |
| First posted | 2021-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diffuse Large B-cell Lymphoma
Intervention
- Drug: Tafasitamab
Primary outcomes
what the primary-completion date above is the date OFTreatment Patterns - Safety
measured 2 Years
Treatment Patterns - Effectiveness (a)
measured 2 Years
Treatment Patterns - Effectiveness (b)
measured 2 Years
Treatment Patterns - Effectiveness (c)
measured 2 Years
Treatment Patterns - Effectiveness (d)
measured 2 Years
Treatment Patterns - Effectiveness (e)
measured 2 Years
Treatment Patterns - Effectiveness (f)
measured 2 Years
Publications
- PMID 32511983 — cited as background
- PMID 34196165 — cited as background
- PMID 37646664 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed